PTI Proteostasis Therapeutics Inc.

-0.07  -1%
Previous Close 4.88
Open 4.84
Price To Book 6.25
Market Cap 244388510
Shares 50,808,422
Volume 411,682
Short Ratio
Av. Daily Volume 3,421,703

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 14 Day trial ongoing. Data timing unclear.
PTI-428 + Kalydeco
Cystic fibrosis
Phase 2 28-day data released December 11, 2017 - showed improvements in FEV1 of 5.2%. Phase 2 28-day data released December 11, 2017 - showed improvements in FEV1 of 5.2%.
Cystic fibrosis
Phase 1 data due 1Q 2019.
PTI-801 + Symdeko: Corrector
Cystic fibrosis
Phase 1 data from fourth cohort are due 1Q 2019.
PTI-801 and PTI-808
Cystic fibrosis
Preliminary data from first cohort due 4Q 2018 with complete data due 1Q 2019.
PTI-428 + PTI-801 + PTI-808
Cystic fibrosis
Phase 2 data due 1Q 2019.
PTI-428 + Symdeko
Cystic fibrosis

Latest News

  1. Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed
  2. Proteostasis Therapeutics to Participate in Upcoming Investor Conferences
  3. Is the Options Market Predicting a Spike in Proteostasis Therapeutics (PTI) Stock?
  4. Proteostasis Therapeutics (PTI) Reports Q3 Loss, Tops Revenue Estimates
  5. Will Proteostasis Therapeutics (PTI) Report Negative Earnings Next Week? What You Should Know
  6. Consolidated Research: 2018 Summary Expectations for Lexington Realty Trust, Proteostasis Therapeutics, PDC Energy, Twenty-First Century Fox, Square, and Sabra Healthcare REIT — Fundamental Analysis, Key Performance Indications
  7. Proteostasis Therapeutics Prices Public Offering of Common Stock
  8. The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares
  9. Proteostasis Therapeutics Announces Proposed Public Offering of Common Stock
  10. 5 Low-Priced Biotech Stocks to Take Advantage of the Market Rout
  11. Why Proteostasis Therapeutics Tumbled 23.2% on Friday
  12. Is Proteostasis Therapeutics Inc (NASDAQ:PTI) Worth US$10.35 Based On Intrinsic Value?
  13. Today’s Research Reports on Stocks to Watch: Proteostasis Therapeutics and Endocyte
  14. PTI Stock News: Why Is Proteostasis Therapeutics Stock Skyrocketing Today
  15. Proteostasis Therapeutics Shares Surge On Positive Preliminary Cystic Fibrosis Trial Results
  16. Proteostasis Therapeutics' rockets to 4-fold gain on massive volume after positive trial results
  17. The Daily Biotech Pulse: Novartis Buys Endocyte, Proteostasis Positive Cystic Fibrosis Trial, 2 IPOs
  18. Proteostasis Therapeutics Announces Positive Preliminary Results from Proprietary Doublet in Cystic Fibrosis Patients
  19. Implied Volatility Surging for Proteostasis Therapeutics (PTI) Stock Options
  20. Report: Exploring Fundamental Drivers Behind Ares Commercial Real Estate, Proteostasis Therapeutics, SunCoke Energy Partners, Fastenal, CNA Financial, and City Office REIT — New Horizons, Emerging Trends, and Upcoming Developments

SEC Filings

  1. EFFECT - Notice of Effectiveness 181218591
  2. 8-K - Current report 181204182
  3. S-3 - Registration statement under Securities Act of 1933 181199679
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163187
  5. SC 13G - Statement of acquisition of beneficial ownership by individuals 181159859
  6. 8-K - Current report 181136707
  7. 424B5 - Prospectus [Rule 424(b)(5)] 181136658
  8. 424B5 - Prospectus [Rule 424(b)(5)] 181133176
  9. 8-K - Current report 181126657
  10. 8-K - Current report 181103711